AI Stock Analysis - Solid Biosciences (SLDB)
Analysis generated August 28, 2025.
Solid Biosciences is a biopharmaceutical company dedicated to advancing transformative treatments for patients with Duchenne muscular dystrophy (DMD). The company focuses on addressing the unmet needs of the DMD patient community by developing innovative therapies that have the potential to improve patient outcomes. Through a rigorous R&D process, Solid Biosciences is positioning itself as a key player in the biotech space.
Stock Alerts - Solid Biosciences (SLDB)
 |
Solid Biosciences | March 13 Price is down by -6.1% in the last 24h. |
|
Solid Biosciences | March 11 Price is down by -6.2% in the last 24h. |
|
Solid Biosciences | March 10 Price is up by 6.6% in the last 24h. |
|
Solid Biosciences | March 9 Price is up by 15% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Solid Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 10 | Sign up | Sign up | Sign up |
| Sentiment | 81 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 60 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,181 | Sign up | Sign up | Sign up |
| X Followers | 1,570 | Sign up | Sign up | Sign up |
| X Mentions | 3 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 68 | Sign up | Sign up | Sign up |
| Linkedin Employees | 147 | Sign up | Sign up | Sign up |
About Solid Biosciences
Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States.
| Price | $7.31 |
| Target Price | Sign up |
| Volume | 4,933,008 |
| Market Cap | $570M |
| Year Range | $3.93 - $8.18 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE TrialMarch 11 - GlobeNewswire |
|
Solid Biosciences Announces Oversubscribed $240 Million Private PlacementMarch 6 - GlobeNewswire |
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 2 - GlobeNewswire |
|
Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptFebruary 13 - SeekingAlpha |
|
 |
Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next MilestonesFebruary 9 - SeekingAlpha |
 |
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular DystrophyFebruary 8 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 380,000 | -380,000 | -46M | -45M | -0.480 |
| Q2 '25 | 0 | 390,000 | -390,000 | -39M | -39M | -0.420 |
| Q1 '25 | 0 | 410,000 | -410,000 | -39M | -39M | -0.590 |
| Q4 '24 | 3.1M | 490,000 | -490,000 | -43M | -42M | -1.000 |
| Q3 '24 | 0 | 410,000 | -410,000 | -33M | -32M | -0.790 |
Insider Transactions View All
| Brooks Gabriel filed to sell 89,466 shares at $5.8. February 18 '26 |
| Tan Kevin filed to sell 99,422 shares at $5.8. February 18 '26 |
| Howton David T filed to sell 105,077 shares at $5.8. February 18 '26 |
| Herzich Paul filed to sell 72,638 shares at $5.8. February 18 '26 |
| Ganot Ilan filed to sell 27,474 shares at $5.8. February 18 '26 |
Similar companies
Read more about Solid Biosciences (SLDB) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Solid Biosciences
The Market Cap of Solid Biosciences is $570M.
Currently, the price of one share of Solid Biosciences stock is $7.31.
The SLDB stock price chart above provides a comprehensive visual representation of Solid Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Solid Biosciences shares. Our platform offers an up-to-date SLDB stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Solid Biosciences (SLDB) does not offer dividends to its shareholders. Investors interested in Solid Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Solid Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
